These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26590436)

  • 1. Enhancing Vaccine Safety Capacity Globally: A Lifecycle Perspective.
    Chen RT; Shimabukuro TT; Martin DB; Zuber PL; Weibel DM; Sturkenboom M
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S364-76. PubMed ID: 26590436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing vaccine safety capacity globally: A lifecycle perspective.
    Chen RT; Shimabukuro TT; Martin DB; Zuber PL; Weibel DM; Sturkenboom M
    Vaccine; 2015 Nov; 33 Suppl 4(0 4):D46-54. PubMed ID: 26433922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in Immunization Safety Monitoring - Worldwide, 2010-2019.
    Salman O; Topf K; Chandler R; Conklin L
    MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(15):547-551. PubMed ID: 33857066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
    Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
    Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization.
    Amarasinghe A; Black S; Bonhoeffer J; Carvalho SM; Dodoo A; Eskola J; Larson H; Shin S; Olsson S; Balakrishnan MR; Bellah A; Lambach P; Maure C; Wood D; Zuber P; Akanmori B; Bravo P; Pombo M; Langar H; Pfeifer D; Guichard S; Diorditsa S; Hossain MS; Sato Y
    Vaccine; 2013 Apr; 31 Suppl 2():B108-14. PubMed ID: 23598471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention.
    Moro PL; Haber P; McNeil MM
    Expert Rev Vaccines; 2019 Oct; 18(10):1091-1101. PubMed ID: 31580725
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of vaccine safety after the events of 11 September 2001: role of cohort and case-control studies.
    Chen RT
    Vaccine; 2004 May; 22(15-16):2047-53. PubMed ID: 15121321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic and immunisation safety surveillance characteristics of countries implementing no-fault compensation programmes for vaccine injuries.
    Mungwira RG; Maure CG; Zuber PLF
    Vaccine; 2019 Jul; 37(31):4370-4375. PubMed ID: 31213377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring and assessing vaccine safety: a European perspective.
    Lopalco PL; Johansen K; Ciancio B; De Carvalho Gomes H; Kramarz P; Giesecke J
    Expert Rev Vaccines; 2010 Apr; 9(4):371-80. PubMed ID: 20370548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system.
    Alguacil-Ramos AM; Muelas-Tirado J; Garrigues-Pelufo TM; Portero-Alonso A; Diez-Domingo J; Pastor-Villalba E; Lluch-Rodrigo JA
    Public Health; 2016 Jun; 135():66-74. PubMed ID: 26976484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of
    Puente Gómez I; Verheust C; Hanssens L; Dolhain J
    Expert Rev Vaccines; 2020 Aug; 19(8):771-779. PubMed ID: 32729745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine Safety.
    Morris L; Swofford S
    Prim Care; 2020 Sep; 47(3):431-441. PubMed ID: 32718441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe.
    Bonhoeffer J; Black S; Izurieta H; Zuber P; Sturkenboom M
    Biologicals; 2012 Sep; 40(5):393-7. PubMed ID: 22902972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017.
    Yoon D; Kim JH; Lee H; Shin JY
    Yonsei Med J; 2020 Jul; 61(7):623-630. PubMed ID: 32608206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-authorization safety surveillance of a liquid pentavalent vaccine in Guatemalan children.
    Asturias EJ; Contreras-Roldan IL; Ram M; Garcia-Melgar AJ; Morales-Oquendo V; Hartman K; Rauscher M; Moulton LH; Halsey NA
    Vaccine; 2013 Dec; 31(49):5909-14. PubMed ID: 24055354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The monitoring of adverse events following immunization.
    Tatley M
    N Z Med J; 2002 Nov; 115(1165):U247; author reply U247. PubMed ID: 12552289
    [No Abstract]   [Full Text] [Related]  

  • 17. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.
    Angelo MG; Zima J; Tavares Da Silva F; Baril L; Arellano F
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):456-65. PubMed ID: 24644078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on the future of postmarket vaccine safety surveillance and evaluation.
    Ball R
    Expert Rev Vaccines; 2014 Apr; 13(4):455-62. PubMed ID: 24606417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suggestions for improving the monitoring of adverse events following immunization in New Zealand.
    Miller M; Turner N
    N Z Med J; 2002 Sep; 115(1162):U186. PubMed ID: 12386665
    [No Abstract]   [Full Text] [Related]  

  • 20. Capacity for a global vaccine safety system: the perspective of national regulatory authorities.
    Graham JE; Borda-Rodriguez A; Huzair F; Zinck E
    Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.